Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital
On Friday, August 14th, 2026, Cathie Wood's ARK ETF made noteworthy adjustments to its portfolio across ARKK, ARKG, and ARKW ETFs. The most notable transaction involved the sale of 10,951 shares of 10X Genomics (TXG), totaling $636,800, signaling a strategic reduction in the firm's stake in the company. In contrast, ARK demonstrated confidence in Perceptive Capital Solutions (FRNM), acquiring 45,010 shares, valued at $522,566.
Other significant purchases included 86,875 shares of Cerus Corp (CERS) and 4,717 shares of Schrödinger Inc (SDGR), both valued at $246,725 and $87,075, respectively. These acquisitions align with ARK's ongoing interest in these companies. Additionally, ARK boosted its stake in the 3iQ Solana Staking ETF (SOLQ.U), purchasing 10,073 shares, totaling $62,452.
On the selling side, ARK divested 1,183 shares of Twist Bioscience (TWST) and 10,340 shares of Brera Holdings (SLMT), both part of a broader strategy to adjust its portfolio. Overall, these trade patterns indicate a strategic realignment by Cathie Wood's ARK ETF, with increased investments in Perceptive Capital and Cerus Corp, while reducing exposure to 10X Genomics and other holdings.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
